Cencora, Inc. $COR Shares Sold by ICW Investment Advisors LLC

ICW Investment Advisors LLC reduced its position in Cencora, Inc. (NYSE:COR) by 0.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,216 shares of the company’s stock after selling 36 shares during the period. Cencora makes up approximately 1.5% of ICW Investment Advisors LLC’s holdings, making the stock its 13th largest holding. ICW Investment Advisors LLC’s holdings in Cencora were worth $3,675,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Cornerstone Planning Group LLC lifted its stake in shares of Cencora by 106.7% in the 1st quarter. Cornerstone Planning Group LLC now owns 93 shares of the company’s stock valued at $26,000 after purchasing an additional 48 shares in the last quarter. Hoey Investments Inc. purchased a new stake in Cencora during the 1st quarter worth approximately $28,000. Costello Asset Management INC purchased a new stake in Cencora during the 1st quarter worth approximately $28,000. Banque Transatlantique SA bought a new stake in shares of Cencora in the 4th quarter valued at approximately $29,000. Finally, Vermillion Wealth Management Inc. bought a new stake in shares of Cencora in the 4th quarter valued at approximately $38,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 14,579 shares of the business’s stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the completion of the sale, the chairman owned 311,913 shares in the company, valued at $91,271,982.06. The trade was a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Robert P. Mauch sold 4,968 shares of the company’s stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $294.11, for a total value of $1,461,138.48. Following the completion of the sale, the chief executive officer owned 42,351 shares of the company’s stock, valued at $12,455,852.61. This represents a 10.50% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,125 shares of company stock valued at $9,993,789. Corporate insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $291.51 on Friday. The business has a 50 day moving average price of $293.02 and a 200 day moving average price of $282.15. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35. The company has a market cap of $56.52 billion, a price-to-earnings ratio of 29.99, a PEG ratio of 1.38 and a beta of 0.58. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.21. The company had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the company earned $3.34 EPS. Research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th will be given a $0.55 dividend. The ex-dividend date is Friday, August 15th. This represents a $2.20 annualized dividend and a yield of 0.8%. Cencora’s payout ratio is presently 22.63%.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on COR. Citigroup boosted their price objective on Cencora from $330.00 to $355.00 and gave the company a “buy” rating in a research report on Thursday, May 8th. Wells Fargo & Company upped their price target on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research report on Wednesday, August 13th. Robert W. Baird upped their target price on Cencora from $314.00 to $350.00 and gave the stock an “outperform” rating in a research report on Thursday, May 8th. Jefferies Financial Group upped their target price on Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research report on Monday, June 30th. Finally, Morgan Stanley set a $330.00 price target on Cencora and gave the stock an “equal weight” rating in a research note on Wednesday, July 16th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $311.25.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.